BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Present Phase 2 Study Results for INM-755 at 12th Annual WCI

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, will be presenting an oral presentation at the 12th World Congress on Itch (“WCI”); the event is scheduled for Nov. 5–7, 2023, in Miami. According to the announcement, the oral presentation is based on an abstract describing the phase 2 clinical study of investigational drug INM-755 cannabinol cream for the treatment of symptoms in patients with rare genetic skin disease called epidermolysis bullosa (“EB”). InMed Pharmaceuticals senior vice president of Clinical and Regulatory Affairs Alexandra Mancini will be presenting. The abstract title is “INM-755 Cannabinol Cream Demonstrates Anti-Itch Activity in Patients with Epidermolysis Bullosa.” Mancini’s presentation is scheduled to begin at 4:08 p.m. ET on Nov. 7. Designed to evaluate the safety of INM-755 CBN cream, the phase 2 within-patient, double-blind study gathered preliminary evidence of the cream’s efficacy in treating symptoms and healing wounds over a 28-day period in patients with EB. The data showed a positive indication of enhanced anti-itch activity for INM-755 cannabinol cream versus the control cream alone. A copy of the poster and other presentation materials will be on the company’s website following the event.

To view the full press release, visit https://ibn.fm/htL8h

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a global leader in the research, development, manufacturing and commercialization of rare cannabinoids, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs. The company also has significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors. For more information, please visit www.InMedPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN